{"nctId":"NCT01369342","briefTitle":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)","startDateStruct":{"date":"2011-07"},"conditions":["Crohn's Disease","Inflammatory Bowel Disease","IBD","Colitis"],"count":640,"armGroups":[{"label":"Placebo IV","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Group 1: Placebo"]},{"label":"Ustekinumab 130 milligram (mg)","type":"EXPERIMENTAL","interventionNames":["Drug: Group 2 ustekinumab 130 mg"]},{"label":"Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)","type":"EXPERIMENTAL","interventionNames":["Drug: Group 3: ustekinumab approximately 6 mg/kg"]}],"interventions":[{"name":"Group 1: Placebo","otherNames":[]},{"name":"Group 2 ustekinumab 130 mg","otherNames":[]},{"name":"Group 3: ustekinumab approximately 6 mg/kg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy\n* Have active Crohn's disease, defined as a baseline Crohn Disease Activity Index (CDAI) score of \\>= 220 and \\<= 450, with confirmation of active inflammation\n* Has failed conventional therapy as demonstrated by having received corticosteroids and/or immunomodulators(ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Have a history of failure to respond to or tolerate an adequate course of corticosteroids and/or immunomodulators (ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Is corticosteroid dependent or has had a history of corticosteroid dependency AND Has not previously demonstrated failure of or intolerance to 1 or more TNF-antagonist therapies (ie, infliximab, adalimumab, or certolizumab pegol) per study criteria\n* Have screening laboratory test results within protocol-specified parameters\n\nExclusion Criteria:\n\n* Patients who have had any kind of bowel resection within 6 months\n* Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent\n* Patients who have received infliximab, adalimumab or certolizumab pegol \\< = 8 weeks before the first administration of study drug\n* Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug\n* Patients with a history of or ongoing chronic or recurrent infectious disease\n* Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Clinical Response at Week 6","description":"Clinical response at Week 6 was defined as a reduction from baseline in the Crohn's Disease Activity Index (CDAI) score of greater than or equal (\\>=) 100 points (in general, CDAI score ranges from 0 to approximately 600余 higher score indicates higher disease activities). Participants with a baseline CDAI score of \\> = 220 to less than or equal (\\< =) 248 were considered to be in clinical response if a CDAI score of less than (\\<) 150 was attained. A decrease in CDAI score over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"108","spread":null},{"groupId":"OG002","value":"116","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Clinical Remission at Week 8","description":"Clinical remission at Week 8 was defined as a Crohn's Disease Activity Index (CDAI) score of \\<150 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Clinical Response at Week 8","description":"Clinical response at Week 8 was defined as a reduction from baseline in the CDAI score of greater than or equal (\\>=) 100 points (in general, CDAI score ranges from 0 to approximately 600余 higher score indicates higher disease activities). Participants with a baseline CDAI score of \\> = 220 to less than or equal (\\< =) 248 were considered to be in clinical response if a CDAI score of less than (\\<) 150 was attained. A decrease in CDAI score over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"121","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Crohn's Disease Activity Index (CDAI) 70 Point Response at Week 6","description":"70-point response is defined as at least 70 points reduction in CDAI score (in general, CDAI score ranges from 0 to approximately 600余 higher score indicates higher disease activities). The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"135","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With CDAI 70 Point Response at Week 3","description":"70-point response is defined as at least 70 points reduction in CDAI score (in general, CDAI score ranges from 0 to approximately 600余 higher score indicates higher disease activities). The CDAI score is used to quantify the symptoms of participants with Crohn's Disease. A decrease in CDAI over time indicates improvement in disease activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":212},"commonTop":["Headache","Nasopharyngitis","Pyrexia","Nausea","Upper Respiratory Tract Infection"]}}}